Listing Thumbnail

    Beat Acute Myeloid Leukemia (AML) 1.0

     Info
    Open data
    |
    Deployed on AWS
    Beat AML 1.0 is a collaborative research program involving 11 academic medical centers who worked collectively to better understand drugs and drug combinations that should be prioritized for further development within clinical and/or molecular subsets of acute myeloid leukemia (AML) patients. Beat AML 1.0 provides the largest-to-date dataset on primary acute myeloid leukemia samples offering genomic, clinical, and drug response. This dataset contains open Clinical Supplement and RNA-Seq Gene Expression Quantification data. This dataset also contains controlled Whole Exome Sequencing (WXS) and RNA-Seq Aligned Reads, WXS Annotated Somatic Mutation, WXS Raw Somatic Mutation, and RNA-Seq Splice Junction Quantification

    Overview

    Beat AML 1.0 is a collaborative research program involving 11 academic medical centers who worked collectively to better understand drugs and drug combinations that should be prioritized for further development within clinical and/or molecular subsets of acute myeloid leukemia (AML) patients. Beat AML 1.0 provides the largest-to-date dataset on primary acute myeloid leukemia samples offering genomic, clinical, and drug response.

    This dataset contains open Clinical Supplement and RNA-Seq Gene Expression Quantification data.

    This dataset also contains controlled Whole Exome Sequencing (WXS) and RNA-Seq Aligned Reads, WXS Annotated Somatic Mutation, WXS Raw Somatic Mutation, and RNA-Seq Splice Junction Quantification

    Features and programs

    Open Data Sponsorship Program

    This dataset is part of the Open Data Sponsorship Program, an AWS program that covers the cost of storage for publicly available high-value cloud-optimized datasets.

    Pricing

    This is a publicly available data set. No subscription is required.

    How can we make this page better?

    We'd like to hear your feedback and ideas on how to improve this page.
    We'd like to hear your feedback and ideas on how to improve this page.

    Legal

    Content disclaimer

    Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.

    Usage information

     Info

    Delivery details

    AWS Data Exchange (ADX)

    AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.

    Open data resources

    Available with or without an AWS account.

    How to use
    To access these resources, reference the Amazon Resource Name (ARN) using the AWS Command Line Interface (CLI). Learn more 
    Description
    BEATAML1.0-COHORT RNA-Seq Gene Expression Quantification
    Resource type
    S3 bucket
    Amazon Resource Name (ARN)
    arn:aws:s3:::gdc-beataml1-cohort-phs001657-2-open
    AWS region
    us-east-1
    AWS CLI access (No AWS account required)
    aws s3 ls --no-sign-request s3://gdc-beataml1-cohort-phs001657-2-open/
    Description
    BEATAML1.0-CRENOLANIB Clinical Supplement
    Resource type
    S3 bucket
    Amazon Resource Name (ARN)
    arn:aws:s3:::gdc-beataml1.0-crenolanib-phs001628-2-open
    AWS region
    us-east-1
    AWS CLI access (No AWS account required)
    aws s3 ls --no-sign-request s3://gdc-beataml1.0-crenolanib-phs001628-2-open/
    Description
    WXS/RNA-Seq Aligned Reads, WXS Annotated Somatic Mutation, WXS Raw Somatic Mutation, RNA-Seq Splice Junction Quantification
    Resource type
    S3 bucket
    Amazon Resource Name (ARN)
    arn:aws:s3:::gdc-beataml1-cohort-phs001657-2-controlled
    AWS region
    us-east-1
    AWS CLI access (No AWS account required)
    aws s3 ls --no-sign-request s3://gdc-beataml1-cohort-phs001657-2-controlled/

    Resources

    Support

    How to cite

    Beat Acute Myeloid Leukemia (AML) 1.0 was accessed on DATE from https://registry.opendata.aws/beataml .

    License

    Similar products